Study to Compare the Safety and Efficacy of ALZ-1101 to Latanoprost in Patients With Intraocular Pressure Inadequately Controlled by Latanoprost
NCT ID: NCT01896180
Last Updated: 2014-09-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
63 participants
INTERVENTIONAL
2013-07-31
2014-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
70 Subjects (35 per arm) will be treated once daily (QD) in the evening with either ALZ-1101 or latanoprost for 28 days.
Efficacy will be assessed at 3 separate times (8 AM, 10 AM and 4 PM) on each treatment visit (Days 0, 7, 14 and 28) by Goldmann applanation tonometry.
Safety assessments will include slit lamp examination/anterior chamber cell and flare grading, ophthalmoscopy/fundus examination, visual acuity, visual field testing and colelction of adverse events. Subject rating of study medication comfort will be collected at each visit.
Primary efficacy endpoint is the between-group comparison of the mean IOP at the 10 am time point at visit 5 (Day 28). Secondary endpoints include the between-group comparisons of the mean change from baseline in IOP at all time-points, between group comparison of the mean change from baseline in diurnal IOP at all post-baseline visits and the proportion of subjects with IOP ≤ 18 mm Hg at all time points at all post-baseline visits.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ALZ-1101
ALZ-1101 ophthalmic solution dosed as 1 drop, once daily in the evening via topical ocular adminstration
ALZ-1101
ALZ-1101 Ophthalmic Solution
Latanoprost
Latanoprost 0.005% ophthalmic solution dosed as 1 drop, once daily in the evening via topical ocular administration
Latanoprost
Latanoprost 0.005% Ophthalmic Solution
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ALZ-1101
ALZ-1101 Ophthalmic Solution
Latanoprost
Latanoprost 0.005% Ophthalmic Solution
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Primary open-angle glaucoma or OH on treatment with latanoprost 0.005% QD.
3. At least one eye with IOP \> 18 mm Hg but ≤ 28 mm Hg at all time points (8 AM, 10 AM, and 4 PM) while on latanoprost monotherapy QD at Screening and Baseline (Day 0) visits. Measurements will be taken each visit at 8 AM, 10 AM, and 4 PM (each ± 30 minutes), with AM measurements of IOP at least 2 hours apart. Screening must be at least one week before but within 2 weeks prior to Baseline.
4. On latanoprost 0.005% QD for at least 4 weeks prior to randomization.
5. Shaffer gonioscopic grade of ≥ 3 (in at least 3 quadrants) in both eyes.
6. Stable corrected Snellen visual acuity (VA) better than 20/200 in the study eye.
7. Central corneal thickness between 480-620 μm in the study eye.
8. Female subjects must be 1-year postmenopausal, surgically sterilized, or women of childbearing potential with a negative urine pregnancy test at Visit 1. Women of childbearing potential must use an acceptable form of contraception throughout the study. Acceptable methods include the use of at least one of the following: intrauterine (intrauterine device), hormonal (oral, injection, patch, implant, ring), barrier with spermicide (condom, diaphragm), or abstinence.
9. Provide signed written consent prior to participation in any study-related procedures.
Exclusion Criteria
2. Presence of a scotoma within 5°of fixation on VF.
3. Aphakia.
4. Use of any antiglaucoma medication in addition to latanoprost QD within 2 weeks prior to Visit 1 or during the study period.
5. Use of any topical ophthalmic steroid or nonsteroidal anti-inflammatory drug (NSAID) within 2 weeks prior to Visit 1 or during the study period.
6. Use of systemic carbonic anhydrase inhibitor within 2 weeks prior to Visit 1 or during the study period.
7. Ocular surgery or ocular laser treatment of any kind within 3 months prior to Visit 1 or during the study period.
8. Any history of glaucoma surgery (laser or non-laser).
9. History of ocular allergy/inflammation and/or severe blepharitis and/or uveitis. Seasonal allergic conjunctivitis is acceptable (avoid enrollment of subjects who may experience seasonal flare-up during the study period). Mild blepharitis/blepharoconjunctivitis, typically associated with prostaglandin usage, is acceptable.
10. History of ocular trauma or ocular infection within 3 months of Visit 1.
11. History of herpes simplex keratitis.
12. Current proliferative diabetic retinopathy or age-related macular degeneration, unless deemed not clinically significant by the Investigator.
13. Severe dry eye (eg, clinically relevant superficial punctate keratitis, epithelial erosions of the cornea, and/or use of dry eye medication \[including artificial tears\] with a frequency exceeding 8 applications per day).
14. Contact lens wear within one week prior to Visit 1 or during the study period (contact lens wear in an untreated fellow eye is allowed).
15. Angle closure or occludable angles (Shaffer gonioscopic grade of \< 3).
16. Cataract that compromises visualization of the fundus.
17. Cup-to-disc (C/D) ratio of \> 0.8.
18. Any secondary glaucoma or OH (eg, congenital glaucoma, closed-angle glaucoma, uveitic glaucoma, or pseudoexfoliation syndrome).
19. Pregnancy or lactation.
20. Uncontrolled asthma (defined as asthma that does not respond to the maximum guideline directed therapy).
21. Allergy to prostaglandin analogues or carbonic anhydrase inhibitors.
22. Allergy to benzalkonium chloride.
23. History of moderate or severe renal or hepatic impairment.
24. Participation in any study of an investigational product within 30 days prior to Visit 1 or at any time during the study period.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alleanza Pharmaceuticals, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Morrow, Georgia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ALZ-1101-101
Identifier Type: -
Identifier Source: org_study_id